GO:0031892 type 2 vasoactive intestinal polypeptide receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031892 describes the molecular function of binding to the type 2 vasoactive intestinal polypeptide receptor (VPAC2), a class B G protein-coupled receptor.
• This binding event is the first step in VPAC2-mediated signaling, which typically elevates intracellular cAMP and activates downstream effectors such as PKA and EPAC.
• The interaction is highly specific, involving distinct receptor domains that recognize VPAC2-selective ligands.
• VIP-VPAC2 signaling regulates intestinal barrier function through a feeding-dependent neuron-ILC3 circuit.
• Dysregulation of VPAC2 binding is implicated in type 2 diabetes and metabolic disorders.
• Studying GO:0031892 requires tools such as radioligand binding assays, cAMP reporters, and CRISPR-engineered cell models.
Description
GO:0031892, type 2 vasoactive intestinal polypeptide receptor binding, is a molecular function term that defines the specific interaction between a ligand and the VPAC2 receptor (also known as the type 2 VIP receptor or PACAP receptor 3). This binding event is a critical node in neuroimmune and metabolic signaling, as it initiates intracellular cascades that modulate intestinal homeostasis, glucose metabolism, and neuronal activity. Understanding this function is essential for researchers dissecting G protein-coupled receptor (GPCR) pharmacology and for developing therapeutics targeting VIP-VPAC2 pathways. The term is distinct from binding to the related VPAC1 receptor, and selective recognition is achieved through distinct receptor domains. In this article, we explore the mechanistic, structural, and disease-related aspects of GO:0031892, and outline how CRISPR-based models can be used to study it.
type 2 vasoactive intestinal polypeptide receptor binding At A Glance
| GO ID | GO:0031892 |
|---|---|
| GO term | type 2 vasoactive intestinal polypeptide receptor binding |
| Ontology | molecular_function |
| Synonym | type 2 vasoactive intestinal polypeptide receptor ligand; type 3 PACAP receptor binding |
| Major function | Binding to VPAC2 receptor, initiating cAMP-dependent signaling |
| Receptor | VPAC2 (VIPR2), a class B GPCR |
| Ligands | VIP, PACAP, and synthetic VPAC2-selective agonists |
| Downstream effectors | cAMP, PKA, EPAC, PAK4 |
| Physiological context | Intestinal barrier regulation, glucose homeostasis |
What Is GO:0031892?
According to the Gene Ontology, GO:0031892 is defined as the binding to a type 2 vasoactive intestinal polypeptide receptor. In other words, it is the molecular function of a ligand (such as VIP or PACAP) physically interacting with the VPAC2 receptor. This function is a prerequisite for receptor activation and downstream signaling.
Why Is type 2 vasoactive intestinal polypeptide receptor binding Important in Cell Biology?
GO:0031892 is important because it represents the molecular trigger for VPAC2-mediated signaling, which plays key roles in neuroimmune crosstalk, intestinal barrier function, and glucose metabolism. Dysregulation of this binding event has been linked to type 2 diabetes and potentially to inflammatory conditions. Moreover, the specificity of ligand-receptor recognition at VPAC2 is a model for understanding GPCR selectivity and for designing targeted therapeutics.
• Regulates intestinal barrier function via VIP neuron-ILC3 circuits.
• Involved in glucose homeostasis and type 2 diabetes pathogenesis.
• Mediates cAMP-dependent activation of PKA and EPAC in pancreatic acinar cells.
• Serves as a paradigm for class B GPCR ligand recognition.
• Potential target for anti-diabetic and anti-inflammatory therapies.
• Distinct from VPAC1 binding, enabling selective pharmacological targeting.
• Modulates neuronal activity and may influence stress-related behaviors.
• Key to understanding neuroimmune interactions in the gut.
Molecular Mechanism of type 2 vasoactive intestinal polypeptide receptor binding
Ligand Recognition and Binding
In simple terms: The ligand docks onto the receptor like a key in a lock.
The binding of VIP or PACAP to VPAC2 involves specific extracellular domains of the receptor. Studies using chimeric receptors and mutagenesis have shown that distinct receptor domains are responsible for selective recognition of VPAC2-selective ligands. The pharmacophore of VIP for VPAC2 has been elucidated, revealing critical residues that confer high-affinity binding.
Receptor Activation and G Protein Coupling
In simple terms: Once the ligand binds, the receptor changes shape and activates a G protein inside the cell.
Ligand binding induces conformational changes in VPAC2 that promote coupling to Gs proteins, leading to adenylyl cyclase activation and cAMP production. This is a hallmark of class B GPCR signaling.
Downstream Signaling Cascades
In simple terms: The signal is passed along like a relay race, activating many proteins.
Elevated cAMP activates protein kinase A (PKA) and EPAC, which in turn regulate effectors such as PAK4 and Na+,K+-ATPase in pancreatic acinar cells. This cascade modulates ion transport, enzyme secretion, and gene expression.
Physiological Context: Neuroimmune Circuit
In simple terms: This binding helps the gut talk to the immune system.
In the intestine, VIP released from neurons acts on VPAC2 on type 3 innate lymphoid cells (ILC3), regulating the intestinal barrier in a feeding-dependent manner. This highlights the role of GO:0031892 in organismal physiology.
Regulation and Desensitization
In simple terms: The receptor can be turned off after prolonged stimulation.
While specific desensitization mechanisms for VPAC2 are not detailed in the provided citations, GPCRs typically undergo phosphorylation and internalization. The binding event itself is subject to regulation by ligand availability and receptor expression levels.
Key Genes Involved in GO:0031892 type 2 vasoactive intestinal polypeptide receptor binding
The following genes and proteins are directly involved in or regulate the function described by GO:0031892.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VIP | Primary ligand for VPAC2 | Knockout models show intestinal barrier defects |
| VIPR2 (VPAC2) | Receptor that binds VIP/PACAP | Central to GO:0031892; target for mutagenesis |
| ADCYAP1 (PACAP) | Alternative ligand | Binds VPAC2 with high affinity |
| GNAS | Gs alpha subunit | Mediates cAMP signaling downstream of VPAC2 |
| PRKACA | PKA catalytic subunit | Effector of cAMP signaling |
| RAPGEF3 (EPAC) | cAMP sensor | Mediates PKA-independent effects |
| PAK4 | Serine/threonine kinase | Activated downstream of VIP in acinar cells |
| ATP1A1 | Na+/K+-ATPase | Regulated by VIP-VPAC2 signaling |
| ILC3 markers (e.g., RORC) | Innate lymphoid cells | Respond to VIP neuron signals |
| SERT (SLC6A4) | Serotonin transporter | Modulated by ketamine, interacting with VIP? |
| NMDAR (GRIN1, GRIN2) | Glutamate receptor | Synergistic with SERT inhibition |
| TRP channels | Ion channels | Modulated by GPCR signaling in tumors |
| VIPR1 (VPAC1) | Related receptor | Distinct binding specificity |
| VIPR2 variants | Receptor polymorphisms | Associated with metabolic traits |
| ADCYAP1R1 (PAC1) | Related receptor | Binds PACAP but not VIP |
| GNAI | Gi alpha subunit | Potential alternative coupling |
| ARRB1/2 | Beta-arrestins | May regulate receptor desensitization |
How Is type 2 vasoactive intestinal polypeptide receptor binding Regulated?
The binding function of GO:0031892 is regulated at multiple levels. Ligand availability (VIP/PACAP secretion) is influenced by feeding state and neuronal activity. Receptor expression levels can be modulated by metabolic status, as suggested by the role of VPAC2 in type 2 diabetes. Additionally, downstream signaling is subject to feedback regulation by kinases such as PKA and EPAC. However, specific transcriptional or post-translational regulation of VPAC2 itself is not detailed in the provided citations.
type 2 vasoactive intestinal polypeptide receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VIPR2 | Type 2 diabetes | Beta-cell-specific knockout or overexpression |
| VIP | Intestinal barrier dysfunction | Intestinal epithelial KO or ligand supplementation |
| VIPR2 | Inflammatory bowel disease | Colitis models in VPAC2 KO mice |
| VIPR2 | Metabolic syndrome | High-fat diet studies with receptor agonists |
| ADCYAP1 | Stress-related disorders | PACAP infusion or knockout models |
Type 2 Diabetes and Metabolic Disorders
VPAC2 (VIPR2) and its binding to VIP are implicated in glucose homeostasis. Therapeutic potential of VIP and VPAC2 in type 2 diabetes has been suggested, with studies showing effects on insulin secretion and beta-cell function. Thus, GO:0031892 may be a target for anti-diabetic strategies.
Intestinal Barrier Dysfunction and Inflammation
The VIP-VPAC2 axis is critical for intestinal barrier integrity. Disruption of this binding leads to impaired barrier function and increased susceptibility to inflammation, as shown in feeding-dependent neuron-ILC3 circuits. This links GO:0031892 to inflammatory bowel diseases.
Neurological and Psychiatric Disorders
VIP and PACAP signaling through VPAC2 is involved in neuronal excitability and stress responses. Although direct evidence for GO:0031892 in depression is limited, related pathways (e.g., SERT and NMDAR) are targeted by rapid antidepressants like ketamine. Further research may uncover roles for VPAC2 binding in mood disorders.
From type 2 vasoactive intestinal polypeptide receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does VPAC2 binding mediate intestinal barrier protection? | VIPR2 knockout mice |
| What is the role of VPAC2 in glucose homeostasis? | Beta-cell-specific VPAC2 knockout |
| Which residues are critical for ligand binding? | Point mutations in VIPR2 extracellular domain |
| Can a tagged VPAC2 be used to track receptor trafficking? | Knock-in of fluorescent tag |
| Does overexpression of VPAC2 enhance cAMP signaling? | VPAC2 overexpression in cell lines |
| What are the downstream effectors of VPAC2 activation? | CRISPR knockout of GNAS, PRKACA, or RAPGEF3 |
How to Study the type 2 vasoactive intestinal polypeptide receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Ligand-receptor affinity | Characterize VPAC2 mutants |
| cAMP assay | Intracellular cAMP levels | Measure receptor activation |
| Western blot | Protein expression and phosphorylation | Assess downstream effectors |
| Immunofluorescence | Receptor localization | Track VPAC2 trafficking |
| CRISPR knockout | Gene function loss | Study VPAC2 in intestinal cells |
| RNA-seq | Transcriptional changes | Identify genes regulated by VIP |
| Co-IP | Protein-protein interactions | Find VPAC2 binding partners |
Radioligand Binding Assays
Direct measurement of ligand-receptor binding affinity using radiolabeled VIP or PACAP. This method is classic for studying GO:0031892 and can be used with membrane preparations from cells expressing wild-type or mutant VPAC2.
cAMP Reporter Assays
Functional assays to measure downstream signaling after receptor binding. cAMP levels can be quantified using luminescent or fluorescent reporters, providing a readout of VPAC2 activation.
CRISPR-Cas9 Genome Editing
Generation of knockout, point mutant, or knock-in cell lines to dissect the specific contributions of VPAC2 and its partners. This allows precise interrogation of GO:0031892 in a cellular context.
Proteomics and Phosphoproteomics
Mass spectrometry-based approaches to identify proteins and phosphorylation events downstream of VPAC2 activation, revealing signaling networks.
How CRISPR Can Be Used to Study GO:0031892 type 2 vasoactive intestinal polypeptide receptor binding
Knockout
CRISPR knockout of VIPR2 or its ligands (VIP, ADCYAP1) can abolish GO:0031892, allowing researchers to study loss-of-function phenotypes in intestinal or metabolic contexts.
Point Mutation
Introducing specific point mutations in VIPR2 can map the binding interface and identify residues critical for ligand recognition, as suggested by earlier mutagenesis studies.
Knock-in
Knock-in of epitope tags or fluorescent proteins into the endogenous VIPR2 locus enables real-time tracking of receptor expression and localization without overexpression artifacts.
Overexpression
Overexpression of VPAC2 in cell lines can amplify signaling for biochemical assays, but may not reflect physiological conditions. It is useful for structure-function studies.
How EDITGENE Supports type 2 vasoactive intestinal polypeptide receptor binding Research
Researchers studying type 2 vasoactive intestinal polypeptide receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function or downstream signaling. EDITGENE provides a suite of CRISPR services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for type 2 vasoactive intestinal polypeptide receptor binding research.
Frequently Asked Questions About type 2 vasoactive intestinal polypeptide receptor binding
What is GO:0031892?
GO:0031892 is the Gene Ontology term for the molecular function of binding to the type 2 vasoactive intestinal polypeptide receptor (VPAC2).
What genes are involved in type 2 vasoactive intestinal polypeptide receptor binding?
Key genes include VIPR2 (encoding VPAC2), VIP, ADCYAP1 (PACAP), and downstream effectors like GNAS and PRKACA.
What is the role of VPAC2 in the intestine?
VPAC2 binding by VIP regulates intestinal barrier function through a neuron-ILC3 circuit.
How is type 2 vasoactive intestinal polypeptide receptor binding studied?
Common methods include radioligand binding assays, cAMP reporters, and CRISPR-based gene editing.
Is VPAC2 involved in diabetes?
Yes, VPAC2 and its ligand VIP have therapeutic potential in type 2 diabetes, influencing glucose homeostasis.
What are the synonyms for GO:0031892?
Synonyms include type 2 vasoactive intestinal polypeptide receptor ligand and type 3 PACAP receptor binding.
What is the difference between VPAC1 and VPAC2 binding?
VPAC1 and VPAC2 are distinct receptors with different ligand selectivity, mediated by different receptor domains.
Can CRISPR be used to study VPAC2 binding?
Yes, CRISPR knockout, point mutation, and knock-in models can precisely dissect VPAC2 function.
What diseases are associated with VPAC2 binding?
Type 2 diabetes, intestinal inflammation, and potentially neurological disorders.
What downstream pathways are activated by VPAC2 binding?
VPAC2 binding activates cAMP, PKA, EPAC, and PAK4 signaling.
Conclusion
GO:0031892, type 2 vasoactive intestinal polypeptide receptor binding, is a fundamental molecular function that initiates VPAC2-mediated signaling with broad physiological and pathological implications. From intestinal barrier regulation to glucose homeostasis, this binding event is a key node in neuroimmune and metabolic circuits. Continued research using advanced CRISPR models and biochemical assays will further illuminate its therapeutic potential.
References
- 1. Talbot J et al.. 2020. Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier.. Nature 579(7800):575-580 PMID: 32050257
- 4. Hou X et al.. 2022. Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes.. Front Endocrinol (Lausanne) 13:984198 PMID: 36204104
- 5. Igarashi H et al.. 2002. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.. J Pharmacol Exp Ther 303(2):445-60 PMID: 12388623
- 6. Ramos-Alvarez I et al.. 2019. Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na(+),K(+)-ATPase in pancreatic acinar cells.. Am J Physiol Gastrointest Liver Physiol 316(2):G263-G277 PMID: 30520694
- 7. Luo H et al.. 2025. Inhibition of SERT and NMDAR synergistically confers rapid antidepressant effects of ketamine.. Natl Sci Rev 12(12):nwaf367 PMID: 41409708
- 8. Juarranz MG et al.. 1999. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.. Mol Pharmacol 56(6):1280-7 PMID: 10570056
